$BJDX

HRT FINANCIAL LP purchased $97K of BJDX

HRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BJDX
Bullish
medium confidence
Mentioned
$BJDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXBullishLow
01

Why it matters

A large owner reported an open-market buy, which can slightly improve sentiment but does not, by itself, change valuation drivers without accompanying operational updates.

02

Market read

Traders may monitor for follow-on ownership activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also does not disclose intent, timeframe, or whether additional buys/sells are planned, limiting signal strength.

Relevance 4/10Novelty 4/10Timing: new Form 4 filed 2026-07-13, covering a 2026-07-09 purchase

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXBullishMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 showing an open-market purchase of 64,047 BJDX shares at $1.51 on 2026-07-09.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a re-rating catalyst.

Evidence & confidence

Form 4 provides a fresh, primary datapoint (new purchase), yet it does not include guidance, trial results, financing, or other company-specific fundamentals that typically drive repricing.

Market effects

No clear sector read-through; this is a single-company ownership transaction.

None indicated.

None indicated.

Counterpoint

The purchase may be routine portfolio rebalancing or driven by liquidity/plan mechanics, so it may not reflect a bullish view on near-term fundamentals.

Key entities

  • Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • HRT Financial LP

    Reported an open-market purchase of BJDX shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

$BJDXMed

Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.

$BJDXMed

Bluejay Completes Enrollment In SYMON-II Sepsis Study

Bluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.

$BJDXMedAI 8/10

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.